Decipher test scores are independently associated with biopsy upgrades in men on active surveillance for Gleason grade group 1 prostate cancer. Higher Decipher scores on the initial test are ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting the Decipher ® Prostate Biopsy genomic classifier (GC) may help guide treatment ...
Imagine having increased muscle weakness for two years before figuring out the cause. That is the shared experience of myasthenia gravis patients. Canadian startup Decipher MedTech is developing a ...
Can Genomic Data Guide the Postoperative Management of Prostate Cancer? Finally, observing the primary end point of metastasis may have been subject to ascertainment bias. 14 Specifically, whereas ...
Decipher Biosciences, which provides genomic testing products for urologic oncology, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering. Decipher's prostate cancer ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene ...
Indian BPO startup Decipher Health Records is in the process of setting up a contact center in Guyana, with the aim of creating 300 jobs in the country. Headquartered in Bangalore, Decipher provides ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback